The investigators undertook a retrospective analysis of patients with advanced urothelial carcinoma who were longitudinally tested for ctDNA (MTM/mL) with a tumor-informed assay while on treatment ...

Dr. Gay concluded his presentation discussing phase l results of a trial assessing radium-223, peposertib, and avelumab in advanced mCRPC with the following take home points: The combination of radium ...

ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Scott T. Tagawa discussing ProstACT Global, a phase 3 study of 177 Lu-rosptamab + standard of care ...

ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Geoffrey Johnson discussing SECuRE, a dose escalation/expansion study to assess the anti-tumor ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. April Rose discussing a ctDNA–directed phase II study of carboplatin in patients with ...

(UroToday.com) The 2025 AUA annual meeting featured the IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder cancer, moderated by Dr. Patrick Hensley, with a debate ...

(UroToday.com) The 2025 AUA annual meeting featured the IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder cancer, moderated by Dr. Peter Black, with a debate between ...

(UroToday.com) The 2025 AUA annual meeting featured the 4 th annual IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder cancer, moderated by Dr. Bernard Bochner, with a ...

(UroToday.com) Historically PSMA-RGS has primarily been reported as a method of identifying lymph node invasion. Dr. Zaurito and team present their exciting findings on the use of PSMA-RGS to identify ...

Eric Kim interviews Aaron Berger about treatment approaches for high-risk prostate cancer and biochemical recurrence. Dr. Berger explains his balanced approach to treatment selection between surgery ...

Sam Chang interviews Alice Yu about three practice-changing areas in urothelial carcinoma. Dr. Yu first discusses the NIAGARA trial, which demonstrated improved pathologic complete response, ...

Weranja Ranasinghe discusses research on developing an immunohistochemistry (IHC) profile to predict response to BCG in non-muscle invasive bladder cancer (NMIBC). In this pilot study analyzing ...